Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

China Human Vaccine Industry Report, 2012-2015
  • USA - English


News provided by

Research Advisor at Reportbuyer.com

Nov 18, 2013, 11:40 ET

Share this article

Share toX

Share this article

Share toX

London (PRWEB) November 18, 2013 -- In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market.

However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each.

In recent years, China has made some achievements in overseas vaccine markets. In 2011-2012, China’s annual human vaccine export volume remained over 9,000 tons (9,840 tons in 2010 was subject to the accidental H1N1 flu event), far more than 8,110 tons in 2009. Moreover, many domestic vaccine companies are still planning overseas markets aggressively.

By the end of 2012, the first batch of Hib vaccine products of Walvax Biotechnology were approved by China Customs and exported to Manila, Philippines for official marketing. Walvax Biotechnology is promoting the product registration in Russia, India, Thailand and other countries. In November 2012, Hualan Biological Engineering mailed three consecutive batches of samples for influenza virus split vaccine to WHO for testing. The company is expected to receive WHO’s spot verification certification in 2013. On March 7, 2013, Tiantan Biological obtained the production approval for polio attenuated live vaccine (liquid OPV). In accordance with the cooperation agreement with Bill & Melinda Gates Foundation in 2011, Tiantan Biological will supply OPV to United Nations International Children’s Emergency Fund (UNICEF) formally.

In addition, it is worth mentioning that the industrialization of the world's first recombinant hepatitis E vaccine (Escherichia coli) developed by Xiamen University and YangShengTang INNOVAX jointly was realized on October 27, 2012. As of the end of 2012, the lot release quantity of the product hit 90,000 person-portions.

China Human Vaccine Industry Report, 2012-2015 mainly contains the following aspects:
Operating environment, status quo, market supply and demand, competition pattern and development prospects of human vaccine in China;
Market supply and demand, competition patterns, market prices and development trends of 10 kinds of products including hepatitis B vaccine, influenza vaccine, Hib vaccine, human rabies vaccine and pneumococcal vaccine in China;
Import & export volume and value as well as import sources & export destinations of human vaccine in China;
Operation, revenue structure, vaccine business and development trends of 11 Chinese vaccine enterprises including Tiantan Biological, Hualan Biological Engineering, Zhifei Biological, Walvax Biotechnology and Sinovac Biotech.

1. Overview of Vaccine Industry

1.1 Definition & Classification
1.2 Industry Chain

2. Overview of China Human Vaccine Industry

2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy
2.2.3 Chinese Biopharmaceutical Market
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Outlook
2.7 Sales Channel

3. Human Vaccine Market Segments in China

3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccine
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DPT Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Situation & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern

4. Human Vaccine Import and Export in China

4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Destinations
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Import Sources

5. Major Human Vaccine Producers in China

5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Clients and Suppliers
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.2.8 Outlook and Forecast
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Clients
5.3.6 R&D and Investment
5.3.7 Outlook and Forecast
5.4 Yunnan Walvax Biotechnology Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 R&D and Investment
5.4.7 Outlook and Forecast
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Clients
5.6.6 Vaccine Business
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation

Read the full report:

China Human Vaccine Industry Report, 2012-2015

http://www.reportbuyer.com/pharma_healthcare/therapeutic/vaccines/china_human_vaccine_industry_report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.